EDSA Stock Analysis: Buy, Sell, or Hold?
EDSA - Edesa Biotech, Inc. Common Shares
$4.43
-0.33 (-6.93%)
▼
5d:
-17.2%
30d:
-21.73%
90d:
-59.25%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When EDSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EDSA is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EDSA is down 17.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDSA is currently trading at $4.43, which is considered oversold relative to its 30-day fair value range of $4.97 to $5.92.
Technical Outlook: Technically, EDSA is in a downtrend. Immediate support is located at $4.17, while resistance sits at $6.67. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: EDSA scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.33 (+268.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDSA is in a downtrend. Immediate support is located at $4.17, while resistance sits at $6.67. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: EDSA scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.33 (+268.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.97 -
$5.92
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 268.7% below Wall St target ($16.33)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.97 -
$5.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.17
Resistance Level
$6.67
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.26
Wall Street Target
$16.33
(+268.7%)
Revenue Growth (YoY)
-99.9%
Share & Embed Analysis
Last updated: August 24, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDSA showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Pardeep Nijhawan
BUY
1000 shares
2026-03-10
Pardeep Nijhawan
BUY
10000 shares
2026-03-05
Pardeep Nijhawan
BUY
10000 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
